Monthly ICOPE Monitoring for Older Adults with Myeloma and Frailty
Tests monthly ICOPE monitoring to detect functional decline in myeloma patients over 70.
Plain-language title generated from the registry record
Registry title: ICOPE Program Feasibility in the Management of Myeloma Patients
Key facts
- Where
- Toulouse, FranceSee the site
Where in France
- CHU de ToulouseToulouse, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Toulouse
- Trial code
- NCT06247189
- Record updated
- 22 December 2025
- Original description
This project proposes to adapt monthly the existing ICOPE (Integrated Care for Older People) MONITOR program for elderly myeloma patients. This adaptation aims to detect earlier functional decline and prevent loss of autonomy.Read full original descriptionShow less
Onco-ICOPE: ICOPE Program Feasibility in the Management of Myeloma Patients Over 70 Years
This project proposes to adapt monthly the existing ICOPE (Integrated Care for Older People) MONITOR program for elderly myeloma patients. This adaptation aims to detect earlier functional decline and prevent loss of autonomy.
Inclusion: Male or female aged over 70 years,; Patient with multiple myeloma; WHO performance status 0-3,; Patient eligible for first- or second-line treatment; Patient willing to participate in ICOPE MONITOR program; Patient or caregiver able to use digital tools of ICOPE MONITOR: application or chatbot (computer or tablet or smartphone); Patient with a life expectancy of more than 3 months,; Patient or caregiver able to understand, read and speak French; Person affiliated or benefiting from a social security; Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).
Exclusion: Patient in palliative care; Patient participating in a study evaluating another frailty prevention program; Patient unable to understand the study; Patient under court protection, guardianship or curatorship,; Patient refusal.